Business Wire

Seoul Semiconductor Hosts European Symposium on “Human-Centric Lighting & Health”

Jaa

Seoul Semiconductor, a global innovator of LED products and technology, hosted a symposium featuring academics and industry insiders that focused on scientifically and objectively demonstrating the effects of light on health and circadian rhythm. Held on March 21 in conjunction with Light + Building 2018, the largest lighting exhibition in the world, Seoul Semiconductor’s symposium was entitled “Human-Centric Lighting & Health.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180329005388/en/

Scene from the SunLike Series LED Symposium held at the 2018 Light + Building Exhibition in Frankfur ...

Scene from the SunLike Series LED Symposium held at the 2018 Light + Building Exhibition in Frankfurt, Germany. (Photo: Business Wire)

The half-day symposium program consisted of several invited experts, including Professor Russell Foster from the University of Oxford, widely accepted as the leading authority in light, sleep, and circadian rhythm research; along with Dr. Manuel Spitschan from the University of Oxford, and Dr. Octavio L. Perez from Mount Sinai Hospital in New York. All three experts gave presentations on the effects of light on human health, and discussed the future direction of lighting.

According to Professor Foster, “Light not only allows us to perceive space, but also plays a critical role in enabling us to perceive time by controlling our circadian rhythm and sleep. To sustain a healthy and happy life, we must get the best sleep and keep our circadian rhythm at an optimum level. We also need to replace today’s artificial lighting systems that hinder our circadian rhythm with more human-centric lighting.”

In another presentation, Dr. Manuel Spitschan from the University of Oxford emphasized the impact of light on the body’s circadian rhythm, stating, “Light has an extremely significant impact on human eyes and brain, due to the photoreceptors in the retina. These receptors perceive red, green, and blue light, and accept the color spectrum in varying degrees.” Dr. Spitschan added, “In particular, intrinsically photosensitive retinal ganglion cells (ipRGC), deliver signals from light via a direct connection to the brain, and react more sensitively to blue light within a certain wavelength. When these cells are activated, it causes the body to inhibit the production of melatonin, a hormone that regulates sleep, therefore affecting the 24-hour circadian rhythm.”

Addressing the importance of sunlight in next-generation architecture standards, Dr. Octavio Perez from Mount Sinai Hospital in New York explained, “Typically, people who live in buildings with great lighting – in other words, buildings that get a lot of sunlight – are healthier and happier, compared to people living in artificially-lit indoor spaces. This is because artificial light features a spectrum that vastly differs from natural sunlight."

“Artificial light, such as fluorescent light and LEDs that emit a spectrum with irregular light waves, hinder the user’s circadian rhythm and eyesight,” Dr. Perez continued. “In the long term, this exposure to artificial light is known to have a negative impact on the human body. However, the SunLike Series natural spectrum LEDs create light with a spectrum that is close to sunlight, offering significant benefits for eye protection and accurate color reproduction, making it an ideal lighting source for architecture, thus we expect it to become more popular in the field moving forward.”

Dr. Perez also stated, “Development in light fixtures which use natural light sources such as SunLike Series LEDs, will revolutionize future standards and design, as the construction industry applies even stricter standards to provide people with good quality light. As such, companies must focus on developing light fixtures that produce natural light.”

SunLike natural spectrum LED technology, developed by Seoul Semiconductor and Toshiba Materials, was awarded the Gold Award by Elektronik, a prestigious German magazine specializing in electronic components that has the largest number of subscribers in Germany.

Seoul Semiconductor global marketing group executive vice president Caleb Won said, “The researchers who were awarded the Nobel Prize in Physiology in 2017 identified the genes that govern the circadian rhythm, which controls the main functions of human behavior, including the level of hormones, sleeping, body temperature, and metabolism. Their research clearly shows the importance of maintaining the 24-hour cycle circadian rhythm formed by natural sunlight.”

Won continued, “This Symposium presented scientific, objective evidence on the impact of light on our circadian rhythm, sleep, and health. It was a meaningful opportunity to increase attention and awareness on the need for light fixtures that offer natural light, and to contemplate future directions for lighting. The SunLike Series LEDs, which recreate light that closely matches the natural spectrum of sunlight, promises to be the next-generation light source to lead the era of human-centric lighting.”

About TRI-R technology

TRI-R is a registered trademark of Toshiba Material Co., Ltd. It is a natural light LED light source technology that reproduces the spectrum of natural sunlight, developed by the concept and spectrum technology of natural light.

About Seoul Semiconductor:

Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – the world’s smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC.

For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com

# Trademarks

WICOP and Acrich are trademarks of Seoul Semiconductor Co., Ltd.

Contact information

Europe
Seoul Semiconductor Europe GmbH
Ariane Heim
Tel: +49 (0)89 450 3690-0
Email: press.eu@seoulsemicon.com
or
North America
Seoul Semiconductor Inc.
Andrew Smith
Tel: +1 (901) 831-6614
Email: andrew.smith@seoulsemicon.com
or
Asia
Seoul Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270
Email: pr@seoulsemicon.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 13:49Tiedote

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 20:41Tiedote

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 20:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 18:42Tiedote

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 17:00Tiedote

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07Tiedote

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme